sevelamer
sevelamer.JPG

CLINICAL USE

Phosphate-binding agent

DOSE IN NORMAL RENAL FUNCTION

1–5 tablets (average: 3–5) 3 times a day with meals; adjust according to serum phosphate level

PHARMACOKINETICS

  • Molecular weight                           :Large
  • %Protein binding                           :No data
  • %Excreted unchanged in urine     : No data
  • Volume of distribution (L/kg)       :No data
  • half-life – normal/ESRD (hrs)      :No data

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unlikely to be dialysed. Dose as in normal renal function
  • HD                     :Unlikely to be dialysed. Dose as in normal renal function
  • HDF/high flux   :Unlikely to be dialysed. Dose as in normal renal function
  • CAV/VVHD      :Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsMycophenolate: may reduce mycophenolate levels

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    Do not use if the patient has swallowing disorders or untreated or severe gastroparesisRenagel is not systemically absorbed One tablet = 800 mg of poly(allylamine hydrochloride) polymerCan be dispersed in 10 mL sodium bicarbonate 8.4% injection if patient is unable to take the tablets.



    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs